Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib

Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news